GlassScriptPhysician profile
Kaye R Christopher
NPI 1881689966
$4,646.77
in general payments reported to CMS, 2019-2025
28 companies · $967 in 2025
The $967 reported for 2025 was more than what 77% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $450 · 2020: $71.70 · 2021: $342 · 2022: $835 · 2023: $811 · 2024: $1,170 · 2025: $967.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,887 · Education: $61.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,887.06 |
| Education | $61.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $561.54 | 2020-2025 | Krystexxa, Tavneos |
| Novartis Pharmaceuticals Corporation | $546.39 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $430.72 | 2019-2025 | Lokelma, Farxiga, Evusheld |
| Bayer Healthcare Pharmaceuticals INC. | $366.42 | 2022-2025 | |
| Horizon Therapeutics Plc | $333.34 | 2021-2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $295.20 | 2022-2025 | Tarpeyo |
| Akebia Therapeutics INC | $287.50 | 2021-2025 | Vafseo, Auryxia |
| Otsuka America Pharmaceutical, INC. | $273.54 | 2019-2025 | Jynarque, Voyxact |
| Glaxosmithkline, LLC. | $206.27 | 2019-2024 | Jesduvroq, Benlysta |
| Vifor Pharma, INC. | $171.17 | 2021-2024 | Veltassa |
| Travere Therapeutics, INC. | $169.19 | 2023-2025 | |
| Bard Peripheral Vascular, INC. | $130.04 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.85 | 2024-2025 | Jardiance |
| Fresenius USA Marketing, INC. | $97.69 | 2021-2024 | Velphoro |
| Novo Nordisk INC | $85.91 | 2024 | Ozempic, Rybelsus |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $85.06 | 2019 | |
| Baxter Healthcare | $76.40 | 2019 | |
| Mallinckrodt Hospital Products INC. | $71.63 | 2022-2023 | Acthar |
| Ani Pharmaceuticals, INC. | $63.47 | 2022 | |
| Aurinia Pharma U.S., INC. | $59.59 | 2023-2025 | Lupkynis |
| Daiichi Sankyo INC. | $48.01 | 2022-2024 | Injectafer |
| Ardelyx, INC. | $41.60 | 2024 | Ibsrela |
| Opko Pharmaceuticals, LLC | $36.41 | 2024 | Rayaldee |
| Nuwellis, INC. | $27.06 | 2022 | |
| Xeris Pharmaceuticals, INC. | $24.62 | 2023 | Keveyis |
| Mallinckrodt Enterprises LLC | $21.89 | 2019 | |
| Lilly USA, LLC | $17.84 | 2025 | Jardiance |
| Incyte Corporation | $13.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaye Christopher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.